{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:53:16Z","timestamp":1791899596917,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T00:00:00Z","timestamp":1467676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    In recent decades, the prognosis of Mantle Cell Lymphoma (\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    ) has been significantly improved by intensified first\u2010line regimens containing cytarabine, rituximab and consolidation with high\u2010dose\u2010therapy and autologous stem cell transplantation. One such strategy is the Nordic\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    2 regimen, developed by the Nordic Lymphoma Group. We here present the 15\u2010year updated results of the Nordic\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    2 study after a median follow\u2010up of 11\u00b74\u00a0years: For all patients on an intent\u2010to\u2010treat basis, the median overall and progression\u2010free survival was 12\u00b77 and 8\u00b75\u00a0years, respectively. The\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    International Prognostic Index (\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    ), biological\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    , including Ki67 expression (\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    \u2010B) and the\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    \u2010B including\n                    <jats:styled-content style=\"fixed-case\">mIR<\/jats:styled-content>\n                    \u201018b expression (\n                    <jats:styled-content style=\"fixed-case\">MIPI<\/jats:styled-content>\n                    \u2010B\u2010miR), in particular, significantly divided patients into distinct risk groups. Despite very long response durations of the low and intermediate risk groups, we observed a continuous pattern of relapse and the survival curves never reached a plateau. In conclusion, despite half of the patients being still alive and 40% in first remission after more than 12\u00a0years, we still see an excess disease\u2010related mortality, even among patients experiencing long remissions. Even though we consider the Nordic regimen as a very good choice of regimen, we recommend inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    .\n                  <\/jats:p>","DOI":"10.1111\/bjh.14241","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T04:12:57Z","timestamp":1467691977000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":212,"title":["15\u2010year follow\u2010up of the Second Nordic Mantle Cell Lymphoma trial (\n                    <scp>MCL<\/scp>\n                    2): prolonged remissions without survival plateau"],"prefix":"10.1111","volume":"175","author":[{"given":"Christian W.","family":"Eskelund","sequence":"first","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"Department of Oncology Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Oncology Lund University Hospital Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"R\u00e4ty","sequence":"additional","affiliation":[{"name":"Department of Haematology Helsinki University Central Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Laurell","sequence":"additional","affiliation":[{"name":"Department of Oncology Uppsala University Hospital Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit Department of Medicine Solna Karolinska Institute Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit Department of Medicine Solna Karolinska Institute Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Husby","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone B.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels S.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Oncology Lund University Hospital Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[{"name":"Department of Haematology Karolinska Institute Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Bentzen","sequence":"additional","affiliation":[{"name":"Department of Haematology Aarhus University Hospital Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Kuittinen","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy Oulu University Hospital Oulu Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grete F.","family":"Lauritzsen","sequence":"additional","affiliation":[{"name":"Department of Oncology Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Nilsson\u2010Ehle","sequence":"additional","affiliation":[{"name":"Section\u00a0of Haematology and Coagulation Medicine Sahlgrenska University Hospital Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Ralfki\u00e6r","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Ehinger","sequence":"additional","affiliation":[{"name":"Department of Pathology Lund University Hospital Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Genetics and Pathology Uppsala University Hospital Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Delabie","sequence":"additional","affiliation":[{"name":"Department of Pathology Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja\u2010Liisa","family":"Karjalainen\u2010Lindsberg","sequence":"additional","affiliation":[{"name":"Department of Pathology Helsinki University Central Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Workman","sequence":"additional","affiliation":[{"name":"Department of Systems Biology Technical University of Denmark Lyngby Denmark"},{"name":"Department of Health Sciences University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Garde","sequence":"additional","affiliation":[{"name":"Department of Systems Biology Technical University of Denmark Lyngby Denmark"},{"name":"Department of Health Sciences University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Elonen","sequence":"additional","affiliation":[{"name":"Department of Haematology Helsinki University Central Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Haematology Rigshospitalet Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13929"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13796"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628792"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119115"},{"key":"e_1_2_8_10_1","first-page":"6A","article-title":"Early consolidation with Myeloablative radiochernotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression\u2010free survival in mantle cell lymphoma \u2010 Long term follow up of a prospective randomized trial","volume":"104","author":"Dreyling M.H.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_2_8_13_1","first-page":"110","article-title":"Alternating courses of 3x CHOP and 3x DHAP Plus Rituximab followed by a high dose ARA\u2010C containing myeloablative regimen and Autologous Stem Cell Transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP Plus Rituximab followed by myeloablative radiochemotherapy and ASCT in Mantle Cell Lymphoma: final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net)","volume":"116","author":"Hermine O.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2466"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-584193"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.12207"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.223"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08228.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237"},{"key":"e_1_2_8_24_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9842"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14241","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T05:29:31Z","timestamp":1696310971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/bjh.14241"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14241","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,5]]},"assertion":[{"value":"2016-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}